文献速递特殊人群用药药物不良反应与药物警戒

2024年第四季度至2025年第三季度新药获批与预期获批进展

Recent and anticipated novel drug approvals (4Q 2024 through 3Q 2025).
PubMed 文献 · Am J Health Syst Pharm · 2025-01-01

本文综述了2024年第四季度至2025年第三季度期间预期获批的新药,从51个待FDA批准的新药中筛选出对医院和诊所具有显著临床和财务影响者进行分析。重点涉及罕见病、癌症、自身免疫病、急性疼痛和抗凝逆转药物,以及治疗移植物抗宿主病的新细胞疗法。结论指出罕见病和癌症的新疗法持续充实当前药物管线。

要点

  • 从51个待FDA批准新药中筛选出预期对医院有显著影响者。
  • 关注领域包括罕见病、癌症、自身免疫病、急性疼痛和抗凝逆转。
  • 新细胞疗法用于移植物抗宿主病,加入待批准靶向治疗行列。

核心结论

  • 罕见病和癌症的新疗法持续增强当前药物管线。

研究设计与样本

  • 本文为药物管线更新综述,分析了2024年第四季度至2025年第三季度期间预期获批的新药,从51个待FDA批准的新药中筛选出预期对医院和诊所具有显著临床和财务影响者进行重点回顾。

主要发现

  • 正在开发的新药涵盖严重罕见病、癌症、自身免疫病、急性疼痛和抗凝逆转等领域。
  • 一种治疗移植物抗宿主病的新细胞疗法加入了待批准的新型靶向治疗行列。

临床怎么用

  • 健康系统药师可利用本文更新药物管线信息,以管理药品目录、分配资源和优化新疗法的临床项目。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Health-system pharmacists play a crucial role in monitoring the pharmaceutical pipeline to manage formularies, allocate resources, and optimize clinical programs for new therapies. This article aims to support pharmacists by providing updates on new and anticipated novel drug approvals. SUMMARY: Selected drug approvals anticipated in the 12-month period covering the fourth quarter of 2024 through the third quarter of 2025 are reviewed. The analysis emphasizes drugs expected to have significant clinical and financial impact in hospitals and clinics, as selected from among 51 novel drugs awaiting US Food and Drug Administration approval. New drugs for severe rare diseases, cancers, autoimmune diseases, acute pain, and reversal of anticoagulation are being developed. Additionally, a new cell therapy for treatment of graft-versus-host disease joined the group of novel targeted therapies for various diseases awaiting approval. CONCLUSION: Novel therapies for treating rare diseases and cancers continue to strengthen the current drug pipeline.

来源:Am J Health Syst Pharm,查看原文。版权归原作者所有。

引用

  1. Rim MH, Dean C, Aliaj E, et al. Recent and anticipated novel drug approvals (4Q 2024 through 3Q 2025). Am J Health Syst Pharm. 2025. PMID: 39578227. doi:10.1093/ajhp/zxae352

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。